A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

NCT03965845 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
NSCLC
CRC
KRAS Gene Mutation

Interventions

DRUG: Telaglenestat (CB-839)
DRUG: Palbociclib Oral Capsule or Tablet [Ibrance]

Sponsor

Calithera Biosciences, Inc